Agenus buys a Xoma plant; Alzheon moves toward Phase III with Alzheimer's drug;

@FierceBiotech: Gilead wins FDA approval for a new HIV combo pill with rivals at its heels. Report | Follow @FierceBiotech

@JohnCFierce: Andy Futreal at MD Anderson is joining my Big Data:2025 panel at . | Follow @JohnCFierce

> Agenus ($AGEN) is acquiring a biologics manufacturing plant from Xoma ($XOMA) for $5 million. More

> Startup Alzheon has launched a pair of clinical trials to prepare its Alzheimer's disease candidate for Phase III development. The company raised $10 million to support the project earlier this year. News

> Cellectis ($CLLS), developing an off-the-shelf version of CAR-T technology, said it's therapy for hard-to-treat leukemia posted positive results in an early-stage study. Item

Medical Device News

@FierceMedDev: Dx Digest: Illumina launches $250M share repurchase program; Foundation Medicine stumbles with Q3 earnings miss. More | Follow @FierceMedDev

@VarunSaxena2: IYCMI from FierceDrugDelivery: Investigational drug enables faster absorption of bioresorbable drug-eluting stents. Article | Follow @VarunSaxena2

@EmilyWFierce: Medicaid calls on Gilead, AbbVie to answer hep C drug pricing questions. FiercePharma article | Follow @EmilyWFierce

> GAO study finds 510(k)-cleared devices account for 94% of unplanned postmarket safety studies. More

> Theranos scouts out new lab director amid testing fallout. Article

Pharma News

@FiercePharma: Australia looks to save cash by cutting scripts for common drugs. FiercePharmaAsia report | Follow @FiercePharma

@EricPFierce: makes sure Denmark gets some of the action as it starts massive build up. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Allergan pumps up its sales rep tally amid Viberzi launch, aesthetics push. FiercePharmaMarketing story | Follow @CarlyHFierce

> Medicaid calls on Gilead, AbbVie to answer hep C drug pricing questions. Report

> Dr. Reddy's feels FDA heat, gets warning letter for three plants. Story

> Sanofi puts 2 units on the block, commits to $1.6B in cuts to turn business around. Article